S
Suzanne Oparil
Researcher at University of Alabama at Birmingham
Publications - 941
Citations - 122414
Suzanne Oparil is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Blood pressure & Angiotensin II. The author has an hindex of 106, co-authored 885 publications receiving 113983 citations. Previous affiliations of Suzanne Oparil include Michigan State University & Oregon Health & Science University.
Papers
More filters
Journal ArticleDOI
Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery.
TL;DR: The data indicate that the sex difference in myointimal proliferation after vascular injury is estrogen dependent, and the responsiveness of this gene to balloon injury of the artery is more rapid and more robust in the male than in the female rat.
Journal ArticleDOI
Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia
Huaibin Li,Shi-Juan Chen,Yiu-Fai Chen,Qing Cheng Meng,Joan Durand,Suzanne Oparil,T. S. Elton +6 more
TL;DR: The findings of concomitant increases in gene transcript levels forET-1 and the ETA and ETB receptors in lung, but not in the great vessels or any other organ examined, are consistent with the hypothesis that increased ET-1 synthesis in the lung contributes to pulmonary vascular remodeling and the maintenance of chronic hypoxic pulmonary hypertension.
Journal ArticleDOI
Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report
Krishna K. Gaddam,Eduardo Pimenta,Stephen J Thomas,Stacey S. Cofield,Suzanne Oparil,Susan M. Harding,David A. Calhoun +6 more
TL;DR: Preliminary evidence is provided that treatment with a mineralocorticoid receptor antagonist substantially reduces the severity of OSA and if confirmed in a randomized assessment, it will support aldosterone-mediated chronic fluid retention as an important mediator of Osa severity in patients with resistant hypertension.
Journal ArticleDOI
Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.
TL;DR: It is concluded that olmesartan, at its starting dose, is more effective than the starting doses of the other ARBs tested in reducing cuff diastolic blood pressure in patients with essential hypertension.
Journal ArticleDOI
Neuronal and adrenomedullary catecholamine release in response to cardiopulmonary bypass in man.
Joseph G. Reves,Karp Rb,E E Buttner,Steven R. Tosone,L. R. Smith,P. N. Samuelson,G R Kreusch,Suzanne Oparil +7 more
TL;DR: A significant increase in catecholamines could jeopardize myocardial protective measures during CPB, and the predominant humoral response to CPB appears to be adrenomedullary release of E.